Subscribe: pubmed: British Journal of H...
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=00lZ-JObmynbfHl6YsaBZPbiu07v3037RZ7ImzQf1eP
Preview: pubmed: British Journal of H...

pubmed: British Journal of H...



NCBI: db=pubmed; Term=British Journal of Haematology[jour]



 



A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
Related Articles

A retrospective study on the management of patients with rituximab refractory follicular lymphoma.

Br J Haematol. 2017 Dec 12;:

Authors: Solal-Céligny P, Leconte P, Bardet A, Hernandez J, Troussard X

Abstract
Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory/relapsed follicular lymphoma patients, this study aimed to describe the real-life management of patients with refractory follicular lymphoma after systemic rituximab-containing regimens (rFL), and rFL patient characteristics. In this retrospective, national, multicentre study, descriptive analyses were mainly performed according to rituximab-containing regimen at rFL diagnosis [rituximab monotherapy (R-MONO), rituximab + chemotherapy (R-COMBO), and ongoing rituximab maintenance (R-MAINTAIN)]. The 459 analysed patients experienced rituximab-refractoriness between October 2013 and September 2015: R-MONO: 58 (13%), R-COMBO: 197 (43%), R-MAINTAIN: 204 (44%). Post-refractoriness strategies were heterogeneous: idelalisib ± rituximab (22%), without anti-lymphoma treatment (21%), rituximab-chemotherapy (21%) and stem cell transplantation (18%). Rituximab was continued in combination in 41% of cases. Chosen strategies varied according to patient age (without anti-lymphoma treatment: 28% of patients if ≥65 years vs. 12% if <65 years old; stem-cell transplantation: 4% vs. 38%), treatment line at rFL, FL International Prognostic Index score and prior treatment. This French retrospective study, the first one conducted in a large cohort of rFL patients, showed that further strategies were highly heterogeneous, depending notably on patient characteristics and previous treatment. These data are the basis for a better understanding of rFL management and for the design of clinical trials in these patients.

PMID: 29230799 [PubMed - as supplied by publisher]